In vitro tests were performed using CST to investigate its role on oxidative damages and inflammatory cytokines. 90% or higher cell viability was observed in CST treated groups from 25 to 200 ${mu}g/m{ell}$ using Raw 264.7 cells. CST showed dose-dependent DPPH scavenging activity, with 91.3% and 92.2% scavenging activities at 400 and 800 ${mu}g/m{ell}$ concentrations, respectively. CST showed dose-dependent suppression activity of ROS production, especially at 200 ${mu}g/m{ell}$ of 41.3%. CST decreased NO production activity, with significant decrease of 16.2% and 33.5% at 100 and 200 ${mu}g/m{ell}$ concentrations, respectively. IL-$1{eta}$, IL-6, MCP-1 production rate were significantly decreased by 30.0%, 27.2%, 22.1% when Raw 264.7 cells were treated with LPS and with CST of 200 ${mu}g/m{ell}$. Also, TNF-${alpha}$ production rate was decreased by 28.6%. The results above indicated therapeutic effect of CST on the AD through anti-oxidative and immune modulatory effect. Various blending of drug substances with CST should be clinically tested.